

# Community-Based Potential Participant Registries

Ed Core Meeting  
October 11, 2013

Joshua Grill, PhD

Assistant Professor of Neurology

Director, Katherine and Benjamin Kagan Alzheimer's Disease Treatment  
Development Program

Director, Recruitment and Education Core

Mary Easton Alzheimer's Disease Research Center at UCLA

# Disclosures

- Site investigator on clinical trials sponsored by the Alzheimer's Disease Cooperative Study (NIA), Janssen AI, Pfizer, Bristol Myers Squibb, Genentech, Avanir, Biogen Idec.
- Principal investigator of single site study sponsored by John Douglas French Foundation for which the medical food is generously donated by Accera Inc.
- Consultant to Avanir Pharmaceuticals, Phloronol, Inc (more than 12 months prior)
- Funding: NIA AG016570, Alzheimer's Association NIRG 12-242511, NACC JIA

# Why Study Recruitment?

- Most AD research fails to meet recruitment goals
- Failure to meet recruitment goals
  - Delays learning/treatment advances
  - Threatens internal validity
  - Raises concerns about generalizability of results
  - Could lead to disparities in disease treatment
- Two action items (1.B.2 and 1.B.3) in the National Plan to Address Alzheimer's disease (AD) aim to increase enrollment to AD clinical trials

# Who Participates in Alzheimer's Disease Clinical Trials?

Characteristic	Community Study <sup>1</sup>	DHA Trial <sup>2</sup>
Age	84 $\pm$ 3.7	76 $\pm$ 8.7
Non-Hispanic White	78%	90%
Education > 12 yrs	13%	63%
% with spouses	29%	65%

<sup>1</sup>Data from the Aging Demographics and Memory Study. Fisher et al., *JAGS*. 2011. <sup>2</sup>Quinn et al. *JAMA* 2010.

# How Can We Increase Trial Enrollment?

- Appeal to previous participants
- Increase community referrals
  - Initiate satellite clinics
- Mailing lists
- Advertising campaigns
- Community outreach/ Community based participatory research
- Initiate potential participant registries

# What is a Potential Participant Registry?

- IRB-approved source of research participants
- Distinct from AD Center's Clinical Core
- Enrollees agree to be contacted about new studies for which they might be eligible

# Types of Registries

- National
  - Alzheimer's Association's TrialMatch®
  - Banner Institute's Prevent AD
  - Research Match
- Local
  - UCLA
  - NYU

# National Registries

- Strengths
  - Large campaigns to increase awareness
    - E.g. Alzheimer's Association chapters
    - Prevent AD partnership with AlzForum
- Weaknesses
  - Low interaction with local researchers
  - Low yield participants
    - E.g. 1% of TrialMatch enrollees have participated in research



# Local Registries

- Strengths
  - Direct interaction with researchers
  - ‘Hands on’ approach may lead to increased research enrollment across a variety of studies
- Weaknesses
  - Resource intense

# IRB Considerations

- May have unique application (separate from human subjects study)
- Minimal risk = expedited review
- Length of 'participation'
- HIPAA considerations
- Listed as recruitment source for subsequent new studies

# Registry Modalities

- Paper consent form that collects data
- Consent-to-be-contacted form
  - Telephonic follow-up, consent, data collection
- Electronic enrollment

# Potential Subject Flow

Sign a  
consent-to-  
be-  
contacted  
form  
(clinical or  
community  
event)



Telephonic  
enrollment  
self-  
reported  
clinical and  
demograph  
info



Query  
registry for  
potentially  
eligible  
participants

David Geffen School of Medicine at UCLA  
Department of Neurology

## INFORMATION AND SIGN-UP SHEET FOR PARTICIPATION IN RESEARCH

**Lay Title: UCLA Easton Alzheimer's Disease Center Potential Subject Pool**

**Technical Title: UCLA Easton Alzheimer's Disease Center Potential Subject Pool**

Principal Investigator: Joshua Grill, PhD

Co-investigators: John Ringman, MD, Liana Apostolova, MD, Po Lu, PsyD, Ellen Woo, PhD, Kathleen Tingus, PhD, Mario Mendez, MD, PhD, Jill Shapira, RN, PhD, Sarah Kremen, MD, Edmond Teng, MD, PhD, Zaldy Tan, MD, Verna Porter, MD, Aaron McMurtry, MD

### INTRODUCTION and PURPOSE

The Mary Easton Center for Alzheimer's Disease (AD) Research conducts clinical research studies related to AD. Signing this form indicates that you are willing to have someone from the Center call you and discuss research opportunities. Signing this form does not obligate you to volunteer for any research program and you can change your mind and refuse discussion with Center staff if you desire.

### ANTICIPATED BENEFITS TO POTENTIAL SUBJECTS and SOCIETY

The studies conducted at the Center aim to improve diagnosis and find a cure for AD.

### PRIVACY AND CONFIDENTIALITY

Information captured in this form or in the follow-up phone call will be confidential and will be shared with no one outside of research staff at the UCLA Easton AD Center.

### PARTICIPATION AND CONSEQUENCES OF WITHDRAWAL

I understand that I am not obligated to sign this form or to participate in research. It has been communicated to me that I may withdraw any recorded information at any time and that doing so will have no impact on the care I receive or my relationship with the staff at UCLA.

### SIGNATURE OF RESEARCH SUBJECT

By signing this form I am granting permission to the research staff of the Mary Easton Center for AD Research to call me and discuss research projects.

I understand that if I grant permission during this phone call, the staff will record basic information about me that will be stored in case future studies for which I might be eligible become available.

Name \_\_\_\_\_ Phone number \_\_\_\_\_

Signature \_\_\_\_\_ Date \_\_\_\_\_

David Geffen School of Medicine at UCLA  
Departamento de Neurología

## INFORMACIÓN Y HOJA DE REGISTRO PARA PARTICIPAR EN INVESTIGACIONES

**Título para el Público: Agrupación de Posibles Participantes en el UCLA Easton Centro de Trastorno de Alzheimer**

**Título Técnico: Agrupación de Posibles Participantes en el UCLA Easton Centro de Trastorno de Alzheimer**

Investigador Principal: Joshua Grill, PhD

Investigadores Colaboradores: John Ringman, MD, Liana Apostolova, MD, Po Lu, PsyD, Ellen Woo, PhD

### INTRODUCCIÓN y PROPÓSITO

El Centro Mary Easton para Investigaciones del Trastorno de Alzheimer (The Mary Easton Center for Alzheimer's Disease [AD] Research) realiza estudios de investigación clínica relacionada con AD. La firma en este formulario indica que usted consiente que alguien de este Centro le llame para hablar acerca de oportunidades de investigación. La firma en este formulario no le obliga a usted a ser un voluntario en algún programa de investigación y si usted lo desea, usted puede cambiar de opinión y negarse a hablar con el personal del Centro.

### BENEFICIOS ANTICIPADOS PARA LOS POSIBLES PARTICIPANTES y para la SOCIEDAD

Los estudios realizados en el Centro tienen el objetivo de mejorar el diagnóstico y encontrar una cura para el Trastorno de Alzheimer.

### PRIVACIDAD Y CONFIDENCIALIDAD

La información que se obtiene en este formulario o en la llamada telefónica de seguimiento será confidencial y no se compartirá con nadie que no sea parte del personal de la investigación en el UCLA Easton AD Center.

### PARTICIPACIÓN Y CONSECUENCIAS DEL RETIRO

Yo entiendo que no tengo ninguna obligación de firmar este formulario para participar en investigaciones. Me han informado que puedo en cualquier momento retirar la información registrada y que no habrá impacto en el cuidado que recibo o mi relación con el personal en UCLA.

### FIRMA DEL SUJETO BAJO INVESTIGACIÓN

Al firmar este formulario permito que el personal del Mary Easton Center for AD Research me llame para hablar acerca de estudios de investigación.

# Consent-to-be-Contacted Venues

- Clinical
  - Direct recruitment (physicians, neuropsychologists)
  - Facilitate referral
- Community
  - Targeted community outreach
  - Quantifying success

# “Data” in Registry

- Demographics
  - Contact information
  - Age
  - Race
  - Ethnicity
  - Education
  - Family history
- Availability of study partner

# “Data” in Registry

- Medical history
  - Neurologic conditions
  - Psychiatric conditions
  - Other comorbidities (hypertension, hypercholesterolemia, diabetes, etc)
  - MRI compatibility
  - Medications



# “Data” in Registry

- Study preference
  - Drug trials
  - Non-drug studies
  - Any
- Preferred mode of contact

# Demographics of the Registry

Characteristic	Summary
Mean Age + SD	70.3 + 13.9
Diagnosis MCI/AD/Dementia	33%
Family history AD	52%
African American	18%
Latino	8%
Study Interests:	
• All studies	67%
• Observational studies only	31%
• Drug studies only	2%


# Results

567 signed consent


282 (49.7%) enrolled

45 (16%) participated

Since 2010 (as of July 2013)



# Efficiency of the Registry



# Future Directions

- Electronify
  - Increase sophistication of data entry, query, outcome assessment
- Increase enrollment
  - UCLA student group (RENOUS): 16 undergraduates trained on Alzheimer's disease biology, risk factors, and research and public speaking

# Acknowledgements

- Jim Galvin, MD, New York University
- ADRC (NIA AG016570)
- Alzheimer's Association (NIRG-12-242511)
- Sidell-Kagan Foundation
- The Alzheimer's Disease Cooperative Study (NIA U01-AG10483)
- NACC (U01 AG016976)

# Summary

- AD research recruitment is slow and fails to represent the disease-suffering population
- Potential participant registries are IRB-approved modes to enhance enrollment
- Potential participant registries may provide
  - Improved enrollment at study initiation
  - More efficient use of research staff time
  - Avenues to increase diversity and representativeness of research samples